
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
BACKGROUND: Intrabuccal administration of amplitude-modulated 27.12 MHz radiofrequency electromagnetic fields (AM RF EMF) resulting in the systemic delivery of low and safe levels of AM RF EMF has shown activity in several forms of cancer.